24.57
2.23 (9.98%)
| Previous Close | 22.34 |
| Open | 23.26 |
| Volume | 7,663,145 |
| Avg. Volume (3M) | 924,053 |
| Market Cap | 1,432,770,304 |
| Price / Sales | 34.32 |
| Price / Book | 1.20 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 1,798.26% |
| Operating Margin (TTM) | -1,221.97% |
| Diluted EPS (TTM) | 11.54 |
| Quarterly Revenue Growth (YOY) | 6.60% |
| Total Debt/Equity (MRQ) | 3.61% |
| Current Ratio (MRQ) | 18.50 |
| Operating Cash Flow (TTM) | -401.46 M |
| Levered Free Cash Flow (TTM) | -237.66 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | 60.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Agios Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -2.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.65% |
| % Held by Institutions | 101.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 48.00 (HC Wainwright & Co., 95.36%) | Buy |
| Median | 32.00 (30.24%) | |
| Low | 20.00 (JP Morgan, -18.60%) | Hold |
| Average | 32.13 (30.77%) | |
| Total | 5 Buy, 3 Hold | |
| Avg. Price @ Call | 25.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 26 Nov 2025 | 38.00 (54.66%) | Buy | 27.38 |
| Truist Securities | 24 Nov 2025 | 32.00 (30.24%) | Buy | 26.49 |
| JP Morgan | 21 Nov 2025 | 20.00 (-18.60%) | Hold | 25.24 |
| B of A Securities | 20 Nov 2025 | 32.00 (30.24%) | Buy | 24.57 |
| Goldman Sachs | 20 Nov 2025 | 25.00 (1.75%) | Hold | 24.57 |
| HC Wainwright & Co. | 20 Nov 2025 | 48.00 (95.36%) | Buy | 24.57 |
| 04 Sep 2025 | 56.00 (127.92%) | Buy | 36.13 | |
| Leerink Partners | 20 Nov 2025 | 34.00 (38.38%) | Buy | 24.57 |
| RBC Capital | 20 Nov 2025 | 28.00 (13.96%) | Hold | 24.57 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Nov 2025 | Announcement | Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease |
| 03 Nov 2025 | Announcement | Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition |
| 30 Oct 2025 | Announcement | Agios Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 17 Oct 2025 | Announcement | Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia |
| 17 Oct 2025 | Announcement | Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia |
| 16 Oct 2025 | Announcement | Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET |
| 04 Sep 2025 | Announcement | Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |